Integrated Translational Cancer Science Center

综合转化癌症科学中心

• 批准号: 9064099
• 负责人: LAURENCE HOWARD BAKER
• 金额: $ 39.77万
• 依托单位: COLD SPRING HARBOR LABORATORY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-12 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9064099
• 关键词: Address; Advanced Malignant Neoplasm; Advocate; Animal Model; Area; Basic Science; Biological Models; Biopsy; Cancer Etiology; Cancer Model; Cancer Patient; Cancer Science; Center for Translational Science Activities; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Treatment; Clinical Trials; Collaborations; Computer Simulation; DNA analysis; Diagnosis; Diagnostic; Disease; Drug resistance; Education; Educational process of instructing; Educational workshop; Enrollment; Fostering; Genetic; Goals; Growth and Development function; Health; Human; Knowledge; Laboratories; Laboratory Finding; Laboratory Research; Lead; Malignant Neoplasms; Medical; Medical Oncologist; Medicine; Minority; Molecular; NCI-Designated Cancer Center; Nurses; Oncogenes; Oncologist; Operative Surgical Procedures; Pathologist; Patients; Pilot Projects; Process; Radiation Oncologist; Randomized Clinical Trials; Research; Resistance; Scientist; Southwest Oncology Group; Surgical Oncologist; Technology; The Jackson Laboratory; Therapeutic; Therapeutic Clinical Trial; Tissues; Translating; Translational Research; Tumor Biology; United States; Update; Xenograft procedure; anticancer research; base; cancer therapy; cancer type; circulating DNA; clinical Diagnosis; clinical practice; clinical trials in animals; experience; functional genomics; gene discovery; genomic data; improved; innovation; insight; meetings; member; model development; mouse model; new technology; novel; novel diagnostics; novel therapeutic intervention; novel therapeutics; oncology; patient population; practical application; predictive marker; programs; radiologist; repository; science education; single cell sequencing; standard of care; symposium; targeted treatment; therapeutic target; therapy resistant; tumor

DESCRIPTION (provided by applicant): The Integrated Translational Science Center (ITSC) formed between SWOG, Cold Spring Harbor Laboratory (CSHL), and The Jackson Laboratory (JAX) provides a powerful combination of clinical and basic research expertise for application to cancer medicine. CSHL and JAX are both NCI-designated Cancer Centers and represent a significant collective experience in cancer gene discovery, the functional genomics of cancer, innovative tumor modeling, and the development of novel technologies to interrogate the disease. SWOG is a premier clinical trials organization that has established the standard of care for multiple cancer types over the past several decades. This alliance will bridge the gap between the laboratory and the clinic by elucidating the key clinical problems and challenges in oncology that can be addressed in the laboratory, discovering new diagnostic and therapeutic approaches that can be integrated into clinical trials, and providing a conduit for clinical trial results to be re-interpreted in the laboratory. This relationship will lead to a clearer understanding of the mechanisms underlying cancer and advance translational research aimed at developing effective targeted therapies. Both CSHL and JAX have used their extensive knowledge of the molecular alterations in human cancer to generate a diverse array of genetically modified or primary human- derived (PDX) xenograft mouse models of human cancer, and these models will be collectively utilized to identify new therapeutic vulnerabilities, determine mechanisms of primary or secondary drug resistance, and develop novel diagnostic strategies. Such information will be used to generate new hypotheses in regard to potential predictive biomarkers that can be studied in randomized clinical trials being conducted by SWOG. Specific examples of novel expertise include single cell sequencing, circulating DNA analysis, co-clinical trials in animal models, computational prediction of resistance from genomic data, and in silico and animal modeling of therapeutic combinations to optimize initial potency and avoid resistance. The scientific endeavors of CSHL and JAX will therefore inform ongoing clinical trials and establish a mechanism for fostering translational cancer research.

描述（由申请人提供）：SWOG、冷泉港实验室 (CSHL) 和杰克逊实验室 (JAX) 组建的综合转化科学中心 (ITSC) 提供了临床和基础研究专业知识的强大组合，可应用于癌症医学。 CSHL 和 JAX 都是 NCI 指定的癌症中心，代表了癌症基因发现、癌症功能基因组学、创新肿瘤模型以及探索疾病的新技术开发方面的重要集体经验。 SWOG 是一家领先的临床试验组织，在过去几十年中为多种癌症类型建立了护理标准。该联盟将通过阐明可以在实验室解决的肿瘤学关键临床问题和挑战，发现可以整合到临床试验中的新诊断和治疗方法，并为在实验室重新解释临床试验结果提供渠道，来弥合实验室和临床之间的差距。这种关系将导致人们更清楚地了解癌症的潜在机制，并推进旨在开发有效靶向疗法的转化研究。 CSHL 和 JAX 都利用其对人类癌症分子改变的广泛知识，生成了多种转基因或原代人源 (PDX) 人类癌症异种移植小鼠模型，这些模型将共同用于识别新的治疗漏洞， 确定原发性或继发性耐药机制，并制定新的诊断策略。此类信息将用于生成有关潜在预测生物标志物的新假设，这些假设可在 SWOG 进行的随机临床试验中进行研究。新颖专业知识的具体例子包括单细胞测序、循环DNA分析、动物模型中的联合临床试验、基因组数据耐药性的计算预测，以及治疗组合的计算机和动物建模，以优化初始效力并避免耐药性。因此，CSHL 和 JAX 的科学努力将为正在进行的临床试验提供信息，并建立促进转化癌症研究的机制。